Skip to main content
Delfa

← All assets

Bapineuzumab

14 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

14

Ongoing

0

Recruiting

0

Completed

5

Sites

874

Countries

27

Endpoints

179

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 179 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
5
Phase 3
7
Not applicable
1

Trials by status

Completed
5
Terminated
8
Unknown
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
57
Safety / tolerability / PK
40
Function / daily living
30
Other (unclassified)
25
Behavior / neuropsychiatric
8
Amyloid biomarkers
6
Caregiver / quality of life
5
Tau biomarkers
4
Neuroimaging
4

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 61 of 179 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

35

Mini-Mental State Examination (MMSE)Cognition

14

Neuropsychiatric Inventory (NPI)Behavior

8

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

4

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

14 of 14

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated346Oct 20122results
NCT00676143Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated288Oct 20122results
NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Completed251Jun 20126
NCT00937352A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated191Sep 2012-
NCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Completed186Apr 20126
NCT00998764A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated184Oct 20121results
NCT00996918A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 3Terminated82Nov 20121results
NCT00606476AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Bapineuzumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2Terminated29Sep 20122
NCT00112073AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 2Completed26Nov 20082
NCT00663026Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 2Completed17Oct 2010-results
NCT00916617Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 2Terminated16Sep 2012-results
NCT00397891Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 1Completed4Feb 20101results
NCT00174525Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease

Bapineuzumab

Alzheimer’s disease

Alzheimer's diseasePh 2Unknown2Apr 2008-
RAPIDRetrieval of Patient Information After Discontinuation

Bapineuzumab

Alzheimer’s disease

Study partner/caregiver requiredNot applicableTerminated0Aug 2012-

Showing 1-14 of 14 trials